Simulations Plus Inc Stock Price, News & Analysis

Simulations Plus (NASDAQ: SLP) reported fiscal 2025 results and reaffirmed fiscal 2026 guidance. FY2025 total revenue was $79.2M (+13% vs prior year) with software revenue $45.8M (58% mix) and services $33.4M (42% mix). Adjusted EBITDA was $22.0M (28% margin) and adjusted diluted EPS was $1.03. The company recorded a $77.2M non-cash impairment, producing a GAAP net loss of $64.7M and diluted loss per share of $3.22 for FY2025. Q4 revenue was $17.5M (-6% YoY) with software down 9% to $9.0M. Management reaffirmed FY2026 guidance of $79–$82M revenue and adjusted diluted EPS $1.03–$1.10 and announced a Virtual Investor Day on Jan 21, 2026 to present its AI product vision.

Simulations Plus (Nasdaq: SLP) provided preliminary fiscal 2025 results and issued fiscal 2026 guidance on October 22, 2025. Key preliminary fiscal 2025 metrics include $79.1M revenue, 13% revenue growth, 58% software mix, 28% adjusted EBITDA margin, and $1.03 adjusted diluted EPS. For fiscal 2026 management issued preliminary guidance of $79M–$82M revenue, 0–4% revenue growth, 57–62% software mix, 26–30% adjusted EBITDA margin, and $1.03–$1.10 adjusted diluted EPS. Results are preliminary and unaudited; final audited results and a full fiscal 2025 report will be filed on Form 10-K and released on December 1, 2025.

Management cited challenging market conditions and outlined a multi‑year Cloud and AI product vision, noting the launch of GastroPlus X.2 on S+ Cloud and planned expansion of AI capabilities.

Simulations Plus (NASDAQ:SLP), a leading provider of cheminformatics and biosimulation solutions for the biopharma industry, has announced its participation in two major investor conferences in September 2025.

CEO Shawn O'Connor will attend the 2025 Wells Fargo Healthcare Conference in Boston on September 3-4, featuring a fireside chat on September 3 at 12:45 PM ET. Additionally, he will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York City on September 10, with a fireside chat scheduled for 2:35 PM ET.

Simulations Plus (Nasdaq: SLP) and the Institute of Medical Biology of the Polish Academy of Sciences (IMB PAS) have published successful results of their artificial intelligence-driven drug design (AIDD) collaboration in ACS Medical Chemistry Letters. The partnership, initiated in 2023, focused on designing novel RORγ/RORγT ligands using ADMET Predictor®.

The results showed that 70% of the 27 tested compounds demonstrated significant RORγT inhibition. The lead compound, featuring a novel indolizine scaffold, showed potent inverse agonist activity, strong efficacy in cellular assays, no significant cytotoxicity, and effectively suppressed proinflammatory Th17 cytokines in human T cells. The compound also displayed favorable drug-like properties as predicted by ADMET Predictor.

Simulations Plus (Nasdaq: SLP) has announced a $1 million investment in Nurocor, a cloud-based software platform provider for clinical development. The investment, made through SLP's Corporate Development Initiative launched in 2024, aims to accelerate innovations in biopharma development.

Nurocor's technology, founded in 2017, focuses on improving efficiency and automation in clinical trials through digitalization. The clinical trial technology sector, valued at $25.7 billion in 2024, is expected to grow at a CAGR of 15.5% from 2025 to 2030. This strategic investment aligns with SLP's mission to expedite drug development and enhance clinical trial processes.

Simulations Plus (Nasdaq: SLP), a provider of biosimulation and cheminformatics solutions, reported Q3 fiscal 2025 results with total revenue increasing 10% to $20.4 million. The quarter saw software revenue grow 6% to $12.6 million and services revenue rise 17% to $7.7 million.

The company recorded a net loss of $67.3 million ($3.35 per share) due to a one-time non-cash impairment charge of $77.2 million. Adjusted EBITDA reached $7.4 million, representing 37% of total revenue. The company implemented a strategic reorganization, transitioning to a functionally-driven operating model.

Management updated FY2025 guidance with revenue expected between $76-80 million and adjusted diluted EPS of $0.93-$1.06. The company is focusing on new AI-driven initiatives across product lines to drive innovation and growth.

[ "Total revenue increased 10% to $20.4 million in Q3 2025", "Services revenue grew 17% to $7.7 million", "Software revenue increased 6% to $12.6 million", "Adjusted EBITDA improved to $7.4 million (37% of revenue) from $5.6 million", "Adjusted diluted EPS increased to $0.45 from $0.27 year-over-year", "Implementation of new AI-driven initiatives across product lines" ]

Simulations Plus (Nasdaq: SLP) has rescheduled its Q3 FY2025 earnings release and conference call from July 2 to July 14, 2025, after market close. The company, which transitioned from a large accelerated filer to a non-accelerated filer, is utilizing the maximum time allowed by regulations before releasing results. SLP reaffirmed its preliminary Q3 revenue guidance of $19-20 million and full-year FY2025 revenue guidance of $76-80 million. The preliminary figures are unaudited and subject to adjustment in the final Form 10-Q, expected to be filed by July 15, 2025. The company provides cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry.

Simulations Plus (Nasdaq: SLP), a provider of cheminformatics, biosimulation, and medical communications solutions for the biopharma industry, announced its participation in the upcoming Citizens Medical Devices and Healthcare Services Forum in Boston. CEO Shawn O'Connor will conduct one-on-one meetings with institutional investors on June 17, 2025. The company's presence at this forum provides an opportunity for institutional investors to engage directly with senior management and learn more about SLP's business strategy and operations.

Simulations Plus (Nasdaq: SLP) announced preliminary Q3 FY2025 revenue expectations of $19-20 million and updated full-year FY2025 revenue guidance to $76-80 million. CEO Shawn O'Connor cited significant market headwinds affecting pharmaceutical and biotech clients, including budget reductions, project cancellations, and delays. While the software segment remains relatively stable, services have been more impacted by market volatility. The company recently implemented a strategic reorganization, shifting from business units to a functionally driven operating model, aimed at streamlining operations and enhancing client engagement. The reorganization represents the final phase of a multi-year transformation focused on operational efficiency and sustainable growth. The company will report detailed Q3 FY2025 results on July 2, 2025.